Table 2b.
Summary of results − II.
| VAS, pain |
VAS, stiffness |
VAS, disability |
|||||||
|---|---|---|---|---|---|---|---|---|---|
| W. somnifera 250 mg (A) | W. somnifera 125 mg (B) | Placebo (C) | W. somnifera 250 mg (A) | W. somnifera 125 mg (B) | Placebo (C) | W. somnifera 250 mg (A) | W. somnifera 125 mg (B) | Placebo (C) | |
| Baseline | 67.25 ± 4.48 | 65.6 ± 4.56 | 63.8 ± 2.78 | 60.25 ± 4.11 | 62.55 ± 4.43 | 61.8 ± 2.71 | 50.45 ± 4.35 | 63.95 ± 4.71 | 58.6 ± 4.30 |
| End of 4 weeks | 60.95 ± 4.22# | 63.05 ± 4.67 | 60.5 ± 3.24 | 55.8 ± 3.83# | 59.45 ± 4.13 | 58.6 ± 2.85 | 46 ± 3.98# | 61 ± 5.03 | 55.35 ± 4.06 |
| End of 8 weeks | 52.9 ± 3.37* | 59.5 ± 4.07 | 58.65 ± 3.56 | 49.4 ± 3.28* | 56.3 ± 4.05 @ | 56.7 ± 2.96 | 40.35 ± 3.64* | 57.75 ± 5.03 | 53.5 ± 4.42 |
| End of 12 weeks | 43.9 ± 3.30* | 53.3 ± 4.02# | 57.4 ± 3.68 | 41.3 ± 3.54* | 50.1 ± 4.12# | 55.2 ± 2.98 | 33.55 ± 3.79* | 52.6 ± 5.37@ | 51.87 ± 4.48 |
| Absolute change at end of 12 weeks | 23.35 ± 3.04* | 12 ± 2.31# | 6.4 ± 1.57 | 18.95 ± 3.08* | 12.45 ± 2.08# | 6.6 ± 1.82 | 17.4 ± 3.08* | 11.35 ± 1.56# | 6.5 ± 1.79 |
| Mean percentage change at end of 12 weeks | 34.73 ± 3.49* | 18.29 ± 3.13# | 10.08 ± 2.71 | 31.4 ± 4.26* | 19.9 ± 3.15# | 10.67 ± 2.93 | 33.7 ± 3.37* | 17.74 ± 3.13# | 11.15 ± 3.18 |
@ p value < 0.05; #p value < 0.01; *p value < 0.001 compared to baseline.
Absolute change in VAS scores:
a) Pain: * A vs B, A vs C (p < 0.001); #B vs C (p < 0.01).
b) Stiffness: * A vs B, A vs C (p < 0.001); #B vs C (p < 0.01).
c) Disability: * A vs B, A vs C (p < 0.001); #B vs C (p < 0.01).
Mean percentage change in VAS scores:
a) Pain: * A vs B, A vs C (p < 0.001); #B vs C (p < 0.01).
b) Stiffness: * A vs B, A vs C (p < 0.001); #B vs C (p < 0.01).
c) Disability: * A vs B, A vs C (p < 0.001); #B vs C (p < 0.01).